Association between polymorphisms in cell cycle genes and advanced prostate carcinoma

Prostate

Volumn 68, Issue 11, 2008, Pages 1179-1186

  Kibel, Adam S ^a,b,c   Jin, Carol H ^a   Klim, Aleksandra ^a   Luly, Jason ^a   Roehl, Kimberly A ^a   Wu, William S ^a   Suarez, Brian K ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b USA   (United States)

^c Wohl Hospital   (United States)

Author keywords

Cancer susceptibility; Cell cycle; Metastatic disease; Prostate carcinoma; Risk assessment

Indexed keywords

ANDROGEN; GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CELL CYCLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE INTERVAL; EUROPEAN AMERICAN; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

AGED; CARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENES, CDC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 48749112916     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20784     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155(3):816-820.
3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271(5):368-374.
4. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152(5 Pt 2):1714-1720.
5. Etzioni R, Penson DF, Legier JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94(13):981-990.
6. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878.
7. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343(2):78-85.
8. Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 2001;61(24):8866-8872.
9. Hunter K, Welch DR, Liu ET. Genetic background is an important determinant of metastatic potential. Nat Genet 2003;34(1):23-24; author reply 25.
10. Kibel AS, Isaacs WB. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology 2000;55(3):316-322.
11. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39(1):41-51.
12. Elledge SJ. Cell cycle checkpoints: Preventing an identity crisis. Science 1996;274(5293):1664-1672.
13. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M, Saito I. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998;16(13):1701-1712.
14. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11(5):1005-1011.
15. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108(2):196-199.
16. Belanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D. Functional promoter SNPs in cell cycle checkpoint genes. Hum Mol Genet 2005;14(18):2641-2648.
17. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119(5):591-602.
18. Bonafe M, Ceccarelli C, Farabegoli F, fAntini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, livieri F, Franceschi C. Retention of the p53 codon 72 arginin allele is associated with a reduction of disease-free and ovarall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003;9(13):4860-4864.
19. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. Association of p53 Codon Arg72Pro and p73 G4C14-to-A4T14 at Exon 2 Genetic Polymorphisms with the Risk of Japanese Breast Cancer. Breast Cancer 2000;10(4):307-311.
20. Shu XO, Moore DB, Cai Q, Cheng J, Wen W, Pierce L, Cai H, Gao YT, Zheng W. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 2005;14(1):91-97.
21. Le Marchand L, Seifried A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 2003;290(21):2843-2848.
22. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002;23(2):257-264.
23. Zheng Y, Shen H, Sturgis EM, Wang LE, Eicher SA, Strom SS, Frazier ML, Spitz MR, Wei Q. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: A case-control study. Carcinogenesis 2001;22(8):1195-1199.
24. Facher EA, Becich MJ, Deka A, Law JC. Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer 1997;79(12):2424-2429.
25. Sakiyama T, Kohno T, Mimaki S, Ohta T, Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C, Kimura J, Maeno G, Hirose H, Eguchi T, Saito D, Ohki M, Yokota J. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 2005;114(5):730-737.
26. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27(1):110-117.
27. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O, Kato T. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003;103(1):116-120.
28. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, Kurokawa K, Yamanaka H. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003;10(4):430-435.
29. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001;49(4):263-266.
30. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003;63(9):2033-2036.
31. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB, Xu J. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004;64(6):1997-1999.
32. Palmieri O, Toth S, Ferraris A, Andriulli A, Latiano A, Annese V, Dallapiccola B, Vecchi M, Devoto M, Surrey S, Fortina P. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin Chem 2003;49(10):1675-1679.
33. Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, Inc.; 1973.
34. Sham P. Statistics in human genetics. New York: John Wiley & Sons, Inc.; 1998.
35. Ott J. A chi-square test to distinguish allelic association from other causes of phenotypic association between two loci. Genet Epidemiol 1985;2(1):79-84.
36. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005;24(17):2899-2908.
37. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005;65(20):9582-9587.
38. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA, Johnson N, Fletcher O, Peto J, Tommiska J, Blomqvist C, Nevanlinna HA, Healey CS, Dunning AM, Pharoah PD, Easton DF, Dork T, Van't Veer LJ. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 2007;67(19):9584-9590.
39. Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomaki K, Pruntel R, Verhoef S, Van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007;15(1):110-114.
40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393(6682):229-234.
41. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine AJ. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006;66(10):5104-5110.
42. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005;173(6):1935-1937.
43. Koike H, Suzuki K, Satoh T, Ohtake N, Takei T, Nakata S, Yamanaka H. Cyclin D1 gene polymorphism and familial prostate cancer: The AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 2003;23(6D):4947-4951.
44. Lin HM, Zhao L, Cheng SY. Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors. J Biol Chem 2002;277(32):28733-28741.
45. Burd CJ, Petre CE, Moghadam H, Wilson EM, Knudsen KE. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol Endocrinol (Baltimore, MD) 2005;19(3):607-620.
46. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13(12):2217-2224.